Vertex Pharmaceuticals Leaps After Phase 3 Studies Meet Primary Endpoints

$123.58's average target is 14.26% above currents $108.16 stock price.

Morgan Stanley's Matthew Harrison and team write that the data on Vertex's cystic fibrosis treatment was "as good as we could have hoped".

03/29/2017 - Vertex Pharmaceuticals Incorporated was upgraded to "outperform" by analysts at BMO Capital Markets. The combination treatment picked up an FDA approval and was subject to some very optimistic sales expectations based on the expansion potential and its price point.

This could also secure the lifecycle of Vertex's cystic fibrosis franchise. The corporation has a market cap of US$26.56 Billion.

Vertex released data on a drug called Tezacaftor that proved superior to its blockbuster Orkambi. The stock, after opening at $106.3, touched a high of $111.88 before paring much of its gains.

VRTX has been the subject of several other research reports. Its Target Price was fixed at 100.25 at an IPO Date of 7/24/1991. The company has a consensus rating of "Buy" and a consensus target price of $104.55.

Vertex Pharmaceuticals Incorporated (NasdaqGS:VRTX) has a current MF Rank of 10111. A certain stock may be considered to be on an uptrend if trading above a moving average and the average is sloping upward. The overall volume in the last trading session was 5.76 Million shares. The day began at US$65.12 but the price moved to US$64.9475 at one point during the trading and finally capitulating to a session high of US$65.5.

Vertex Pharmaceuticals (NASDAQ:VRTX) last posted its quarterly earnings results on Wednesday, January 25th. According to their predictions High & Low revenue estimates are 709.27 Million and 448 Million respectively. Vertex Pharmaceuticals had a negative return on equity of 2.15% and a negative net margin of 6.76%. USB's profit will be $1.37 billion for 16.18 P/E if the $0.80 EPS becomes a reality. Parini Michael sold $296,631 worth of stock or 3,450 shares. There may be various price targets for a stock. An RSI reading above 80 indicates that a stock is overbought while anything below 20 is oversold. The transaction was disclosed in a filing with the SEC, which is available at this hyperlink. Technical analysis can help recognize key technical price levels in the stock. Following the completion of the sale, the director now directly owns 276,225 shares in the company, valued at $22,783,038. The company has grown 11.01% in past 3 months and in the last five trades has moved up 6.01%. Company insiders own 1.90% of the company's stock. Institutional investors and hedge funds own 94.85% of the company's stock. The Motley Fool recommends Vertex Pharmaceuticals.

CVR Energy, Inc. (CVI) surprised the stock market in its last reported earnings when it earned $0.08 a piece versus the consensus-estimated -$0.14. Global X Management Co. Capital World Investors increased its position in Vertex Pharmaceuticals by 2.8% in the third quarter. LLC now owns 1,557 shares of the pharmaceutical company's stock valued at $136,000 after buying an additional 955 shares during the last quarter. Two Sigma Investments LP raised its stake in shares of Vertex Pharmaceuticals by 143.1% in the fourth quarter. Narrowing in a bit closer, the 5 month price index is 1.14318, the 3 month is 1.19670, and the 1 month is now 1.01215.

Vertex Pharmaceuticals (VRTX) soared to the top of the S&P 500 today after a successful drug trial. It focuses on development and commercializing therapies for the treatment of cystic fibrosis; infectious diseases, including viral infections, such as influenza, and bacterial infections; autoimmune diseases, such as rheumatoid arthritis; cancer, inflammatory bowel disease; and neurological disorders, including pain, Huntington's disease and multiple sclerosis.

  • Zachary Reyes